Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG)
- Main trialPhase 3
- “EA-230 is a new therapy that may help people recover faster and have fewer problems after bypass surgery. In an earlier clinical trial, participants who received EA-230 during Coronary Artery Bypass surgery stayed in the Intensive Care Unit (ICU) and the hospital for a shorter time and had fewer serious complications, compared to those who received a placebo (an inactive therapy). The use of EA-230 was safe and well tolerated. This trial will test EA-230 in more participants to see if it really works and is safe to use in the future. This is a Phase III trial. It will take place in multiple…”In the company’s words, NCT07357675 on ClinicalTrials.gov
Other drugs for Coronary Artery Disease (CAD)
- XTR004Sinotau Pharmaceutical Group · Phase 3
- ObicetrapibNewAmsterdam Pharma · Phase 3
- Bempedoic acid/ezetimibeDaiichi Sankyo · Phase 3
- ZiltivekimabNovo Nordisk · Phase 3
- RetatrutideEli Lilly · Phase 3
- InclisiranNovartis · Phase 3
Coming up1
- 1 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Oct 2027 | A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026